Steelers RB DeAngelo Williams Hugs Breast Cancer Survivors Before Win vs. Jets : bleacherreport

as mentioned in bleacherreport

Steelers RB DeAngelo Williams Hugs Breast Cancer Survivors Before Win vs. Jets

Steelers RB DeAngelo Williams Hugs Breast Cancer Survivors Before Win vs. Jets

Use your ← → (arrow) keys to browse more storiesBefore Sunday's 31-13 win over the New York Jets, Pittsburgh Steelers running back DeAngelo Williams met with and hugged a group of breast cancer survivors on the sideline.Williams' mother died of the disease in 2014.He dyed his hair pink that September and has kept the look ever since.Last season, D-Will wanted to wear pink accessories for all 16 games—instead of exclusively in October—but the NFL denied that request, according to ESPN.com's Field Yates.


furthermore forbes

Encouraging Results For Ribociclib In Advanced Breast Cancer

Encouraging Results For Ribociclib In Advanced Breast Cancer




in like manner onclive

Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer

Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer

Gabriel N. Hortobagyi, MDReferencesHortobagyi GN, Stemmer SM, Burris HA, et al.First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer.Presented at: 2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark.Abstract LBA1.


not to mention medpagetoday

Anti-CDK4/6 Boosts PFS in Metastatic Breast Cancer

Anti-CDK4/6 Boosts PFS in Metastatic Breast Cancer

COPENHAGEN -- The addition of a targeted agent to endocrine therapy for metastatic breast cancer led to unprecedented improvement in progression-free survival (PFS) that will have a "paradigm changing" effect on clinical management, an investigator said here.Patients who received the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib in addition to letrozole (Femara) had a 44% reduction in the PFS hazard compared with patients treated with letrozole alone.The median PFS (primary endpoint) was 14.7 months with letrozole but had yet to be reached with letrozole plus ribociclib, "but it is expected to far exceed what the control arm did," Gabriel N. Hortobagyi, MD, reported at the European Society for Medical Oncology (ESMO) conference."We did a number of preplanned subset analyses, and the benefit was present in all subsets, regardless of age, performance status, and extent or location of metastases," Hortobagyi, of the University of Texas MD Anderson Cancer Center, said during an ESMO press briefing.